ArticleNuclear medicine communications2025
Interpretation of basal nuclei in brain dopamine transporter scans using a deep convolutional neural network.
Article in Nuclear medicine communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Examination of simple artificial intelligence-based analysis of dopamine transporter scintigraphy for supporting a diagnosis of Parkinson's disease.Annals of nuclear medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFunctional imaging using the dopamine transporter (DAT) as a biomarker has proven effective in assessing dopaminergic neuron degeneration in the striatum. In assessing the neuron degeneration, visual and semiquantitative methods are used to interpret DAT single-photon emission tomography (SPECT) scans based on striatal to background activity, striatal shape, and symmetry. Visual analysis, however, is subjective and reviewer dependent, whereas semiquantitative methods are operator dependent. Our goal in the current study was to derive results via deep learning to facilitate the clinical diagnosis of Parkinson's disease (PD).
methodsThis retrospective study collected data from 416 patients with clinically uncertain Parkinsonian syndrome who underwent DAT SPECT via 99m Tc-TRODAT-1 ([2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3,2,1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino]ethanethiolato (3-)- N2,N2',S2,S2' ]oxo-[1 R -( exo - exo )]). Transfer learning was used to estimate the degree of dopaminergic neuron degeneration in the caudate and putamen for use in classifying images according to stage. Three pretrained models - Xception, InceptionV3, and ResNet101 - were retrained and tested after undergoing transfer learning for the classification of striatum dopaminergic neuron degeneration.
resultsOverall, the performance of Xception exceeded that of InceptionV3 and ResNet101. The accuracy, macro F1 score, and kappa value of the proposed caudate classification model were 81.93%, 0.70, and 0.64, respectively. The accuracy, macro F1 score, and kappa value of the proposed putamen classification model were 88.75%, 0.64, and 0.61, respectively.
conclusionThe proposed deep convolutional neural network provided a good model by which to interpret DAT SPECT of basal nuclei. We believe that the model could be used as an auxiliary tool to facilitate image interpretation and enhance accuracy in the diagnosis of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.